Literature DB >> 12694502

Oral erosive/ulcerative lichen planus: preliminary findings in an open trial of sulodexide compared with cyclosporine (ciclosporin) therapy.

Felice Femiano1, Fernando Gombos, Crispian Scully.   

Abstract

OBJECTIVE: To study the effect of the heparinoid sulodexide systemically, compared with topical cyclosporine (ciclosporin), on chronic oral erosive/ulcerative lichen planus. STUDY
DESIGN: An open nonrandomized trial was conducted in two groups of 10 Italian patients with lichen planus, with subjective assessment of pain and assessment of ulceration amelioration by nonblinded clinicians.
RESULTS: Comparable pain relief and amelioration of erosions/ulcers were seen in patients on sulodexide and in those on ciclosporin, but with faster healing in those on sulodexide.
CONCLUSIONS: Sulodexide appears to be as effective, and perhaps more effective, than topical ciclosporin in the therapy of oral lichen planus, and is less expensive, but full double-blind placebo-controlled studies are required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694502     DOI: 10.1046/j.1365-4362.2003.01770.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  A topical heparinoid-containing product improves epidermal permeability barrier homeostasis in mice.

Authors:  Ye Yao; Pan Guo; Xiaoyue Feng; Chunping Shen; Junkai Huang; Jiechen Zhang; Peter M Elias; Lizhi Hu; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2019-07-04       Impact factor: 3.960

2.  A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus.

Authors:  M Georgaki; E Piperi; V-I Theofilou; E Pettas; E Stoufi; N-G Nikitakis
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-03-01

3.  Oral lichen planus: comparative efficacy and treatment costs-a systematic review.

Authors:  Shaiba Sandhu; Brittany A Klein; Malak Al-Hadlaq; Prazwala Chirravur; Amal Bajonaid; Yuanming Xu; Rossella Intini; Mai Hussein; Piamkamon Vacharotayangul; Herve Sroussi; Nathaniel Treister; Stephen Sonis
Journal:  BMC Oral Health       Date:  2022-05-06       Impact factor: 3.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.